Zoliflodacin

Zoliflodacin
Clinical data
Other names	AZD0914; ETX0914
Pregnancy; category	Not classified yet;
Routes of; administration	Oral
Drug class	Antibiotic
Legal status
Legal status	US: Investigational New Drug; Investigational;
Pharmacokinetic data
Bioavailability	97.8%
Metabolism	Hepatic
Onset of action	Fasted: 1.5–2.3 h; Fed: 4 h;
Elimination half-life	5.3–6.3 h
Excretion	Faeces (79.6%); Urine (18.2%);
Identifiers
CAS Number	1620458-09-4;
PubChem CID	76685216;
DrugBank	12817;
UNII	FWL2263R77;
KEGG	D11726;
Chemical and physical data
Formula	C22H22FN5O7
Molar mass	487.444 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C[C@@H]1CN2[C@H]([C@@H](O1)C)C3(CC4=C2C(=C5C(=C4)C(=NO5)N6[C@H](COC6=O)C)F)C(=O)NC(=O)NC3=O;
	InChI InChI=1S/C22H22FN5O7/c1-8-7-33-21(32)28(8)17-12-4-11-5-22(18(29)24-20(31)25-19(22)30)16-10(3)34-9(2)6-27(16)14(11)13(23)15(12)35-26-17/h4,8-10,16H,5-7H2,1-3H3,(H2,24,25,29,30,31)/t8-,9+,10-,16+/m0/s1; Key:ZSWMIFNWDQEXDT-ZESJGQACSA-N;

Zoliflodacin (development codes AZD0914 and ETX0914) is an experimental antibiotic that is being studied for the treatment of infection with Neisseria gonorrhoeae (gonorrhea).^[1] It has a novel mechanism of action which involves inhibition of bacterial type II topoisomerases.^[2] It is being developed by Entasis Therapeutics and is (as of 2020) in Phase III clinical trials.^[3]

References